Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives

Muhannad Alsyouf, Phillip Pierorazio, Jason Groegler, Brian Hu

Research output: Contribution to journalReview articlepeer-review

Abstract

Chemoablation is an emerging treatment for urothelial carcinomas. This review provides an overview of the evidence for intracavitary chemoablation in the treatment of urothelial carcinomas. The benefits of such agents include a reduction in morbidity and diseased organ preservation. While numerous agents have shown promise, research is limited due to small patient cohorts, varying follow-up, and no standardized methodology to assess response. Therefore, to date, chemoablation has not been widely adopted. This may change as a novel mitomycin formulation has recently been approved for treating low-grade upper tract urothelial carcinoma. Future studies are ongoing which evaluate other promising chemoablation options in urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)28-37
Number of pages10
JournalUrology
Volume144
DOIs
StatePublished - Oct 2020

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives'. Together they form a unique fingerprint.

Cite this